FDA Inspection
Bristol-Myers Squibb CompanyBristol-Myers Squibb Company – FDA Inspection, Apr 5, 2017
Record Details
This FDA Inspection record concerns Bristol-Myers Squibb Company, with an inspection on April 5, 2017, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · 8a6b3347-61a7-4888-b4e1-003a1e2120e8
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1008167
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
Other FDA inspections of Bristol-Myers Squibb Company
7| Date | Classification | Office | Project area |
|---|---|---|---|
| August 27, 2026 | Not classified | New England District Office | Human Cellular, Tissue, and Gene Therapies |
| July 8, 2025 | Not classified | New England District Office | |
| May 5, 2023 | Not classified | New England District Office | |
| January 10, 2020 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| October 21, 2016 | Not classified | New England District Office |
Other documents for Bristol-Myers Squibb Company
- FDA Inspection 1338128 - 2026-08-27
- FDA Inspection 1272436 - 2025-07-08
- FDA Inspection 1206159 - 2023-05-05
- FDA Inspection 1115960 - 2020-01-10
- FDA Inspection 988152 - 2016-10-21
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.